TradingView report covering Haoxi Health Technology Limited (Class A) (HAO) market action, institutional positioning, and fundamental catalysts.
Why HAO Stock surged +2.08% Today — RQD Quant Desk Flash
Haoxi Health Technology Limited (Class A) (HAO) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is HAO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Haoxi Health Technology Limited (Class A) (NASDAQ: HAO) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $1.96 (+2.08% 1D, market cap $1.2M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 7/20. Across 132 tracked Communication Services issuers, HAO ranks #101 in composite RQD confidence.
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does HAO compare to TNMG and FCDH in the Communication Services sector?
▼
Within the Communication Services sector (Advertising), HAO carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of 96.0%, and ROIC of —. By comparison, TNMG (TNL Mediagene) holds a D+ grade (53/100 RQD, P/E N/A, ROIC —, cap $3.0M) and FCDH (Forcendra Holding Limited (Class A)) posts a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $3.1M). Among the 5-stock peer group, HAO leads on earnings multiple (N/A) while YDKG leads on capital efficiency (-11.5% ROIC).
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for HAO?
▼
Per HAO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001954594), Haoxi Health Technology Limited (Class A) generated $537.6K in revenue (-54.6% YoY), $3.9M in net income, and -$3.4M in free cash flow against $0 in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Communication Services with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 92.8% Gross Margin
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
⚔️ Adversarial Opposing Case: What Could Spark a HAO Turnaround Squeeze
While HAO currently carries a cautious 36/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Communication Services with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.63) and Max Pain ($2.06) forces dealer call-delta covering toward $4,569.60.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.16% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Why HAO Stock surged +2.08% Today — RQD Quant Desk Flash
Haoxi Health Technology Limited (Class A) (HAO) surged +2.08% to $1.96, trading at 2% of its 52-week range ($1.6 – $4352). Stretched risk/reward at current multiples (96% profit margin) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 2% of its 52-week range ($1.6 – $4352) with RSI-14 at 35.4 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $1.96 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 92.8% gross margin and $0 annual free cash flow.
Yahoo Finance report covering Haoxi Health Technology Limited (Class A) (HAO) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Haoxi Health Technology Limited (Class A) (HAO) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Haoxi Health Technology Limited (Class A) (HAO) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Haoxi Health Technology Limited (Class A) (HAO) market action, institutional positioning, and fundamental catalysts.
RTTNews report covering Haoxi Health Technology Limited (Class A) (HAO) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Haoxi Health Technology Limited (Class A) (HAO) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Haoxi Health Technology Limited (Class A) (HAO) market action, institutional positioning, and fundamental catalysts.
Gainers Dreamland (NASDAQ:TDIC) stock increased by 18.0% to $1.77 during Tuesday's pre-market session. The market value of their outstanding shares is at $5.1 million. TEN Hldgs (NASDAQ:XHLD) shares increased by
Gainers Treasure Global (NASDAQ:TGL) stock increased by 55.2% to $0.34 during Monday's pre-market session. Global Interactive (NASDAQ:GITS) stock increased by 12.52% to $1.4. The market value of their outstanding
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring HAO)
- ✓Walkthrough of HAO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
HAO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -54.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on HAO today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for HAO. Explore sector supply chains on /butterfly.
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (HAO)
1. Head-to-Head Communication Services Peer Comparison (HAO vs. TNMG, FCDH, YDKG, INUV)
Industry: Advertising (23 Tracked Issuers)Across 132 tracked Communication Services securities in the Roarable RQD universe, Haoxi Health Technology Limited (Class A) (HAO) ranks #101 by composite RQD confidence (36/100, grade D-) and #131 by equity capitalization ($1.2M). Within this direct 5-issuer industry benchmark cohort, HAO leads on earnings valuation at N/A trailing P/E, while YDKG leads on capital efficiency and profitability with -11.5% ROIC and -2.5% gross margin. TNMG currently holds the highest overall quantitative score in the immediate peer group at 53/100 (D+) compared with HAO at 36/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| HAO
ACTIVE
Haoxi Health Technology Limited (Class A) | D- | 36/100 | — | 96.0% | — | +2.08% | $1.2M | Benchmark Subject |
| TNMG TNL Mediagene | D+ | 53/100 | — | — | — | +6.68% | $3.0M | /tnmg-vs-hao → |
| FCDH Forcendra Holding Limited (Class A) | E | 26/100 | — | 23.7% | -35.0% | -4.36% | $3.1M | /fcdh-vs-hao → |
| YDKG Yueda Digital Holding Class A Ordinary Share | D | 48/100 | — | -2.5% | -11.5% | -1.11% | $5.0M | /ydkg-vs-hao → |
| INUV Inuvo Inc. | E | 26/100 | — | 74.5% | -35.0% | +2.41% | $6.8M | /inuv-vs-hao → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-06-30 • CIK 0001954594In its most recent audited fiscal period (FY2025, filed 2025-06-30), Haoxi Health Technology Limited (Class A) (HAO) reported GAAP revenue of $537.6K (-54.6% vs. FY2024 revenue of $1.2M , and -98.1% cumulative change since FY2023) , GAAP net income of $3.9M, operating cash flow of -$3.4M, and free cash flow of -$3.4M (-318.2% YoY). On the balance sheet, HAO closed FY2025 with $0 in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-06-30 | $537.6K | $3.9M | -$3.4M | -$3.4M | — | — |
| FY2024 (FY) | 2024-06-30 | $1.2M | $1.3M | -$747.6K | -$802.9K | $22.1M | — |
| FY2023 (FY) | 2023-06-30 | $28.2M | $969.8K | -$872.1K | -$872.1K | — | — |
3. HAO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs HAO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Haoxi Health Technology Limited (Class A) (NASDAQ: HAO) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $1.96 (+2.08% 1D, market cap $1.2M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 7/20. Across 132 tracked Communication Services issuers, HAO ranks #101 in composite RQD confidence.
How does HAO compare to TNMG and FCDH in the Communication Services sector?
Within the Communication Services sector (Advertising), HAO carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of 96.0%, and ROIC of —. By comparison, TNMG (TNL Mediagene) holds a D+ grade (53/100 RQD, P/E N/A, ROIC —, cap $3.0M) and FCDH (Forcendra Holding Limited (Class A)) posts a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $3.1M). Among the 5-stock peer group, HAO leads on earnings multiple (N/A) while YDKG leads on capital efficiency (-11.5% ROIC).
What are the biggest fundamental strengths and SEC risk factors for HAO?
Per HAO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001954594), Haoxi Health Technology Limited (Class A) generated $537.6K in revenue (-54.6% YoY), $3.9M in net income, and -$3.4M in free cash flow against $0 in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Communication Services with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is HAO trading relative to its 50-day, 200-day, and 52-week technical levels?
HAO last traded at $1.96 (+2.08% on volume of 9,277 shares), positioning the stock -25.48% below its 50-day simple moving average ($2.63) and -99.83% below its 200-day simple moving average ($1,144.32). Across its 52-week range of $1.60 to $4,352.00, HAO sits at the 0.0% percentile with a 14-day RSI of 35.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.72 to $2.20).
HAO — Haoxi Health Technology Limited (Class A): What the Facts Mean to a Prospective Investor
1. Roarable Rating Brief: What This Means to a Prospective Investor
HAO scores 36 out of 100 and receives a letter grade of D-, with the verdict label "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are:
- Fundamental Cash Engine: 8 / 20. The rating reports ROIC at 0% and FCF yield at 0%. For a prospective investor, this means the business is not currently generating returns on invested capital or free cash relative to its valuation, so there is little cash-based support for the share price.
- Whale 13F Flow: 3 / 20. This pillar reflects institutional accumulation and options positioning, and it is the lowest-scoring pillar. Weak institutional support means fewer large holders are signaling conviction, which can increase the price impact of any selling.
- Insider Conviction: 7 / 20. This pillar covers SEC Form 4 and Congressional PTR cluster flow. The low score indicates limited insider or congressional buying conviction.
- Macro Regime Fit: 8 / 20. The rating reports Beta of 1.0 and a sector sensitivity assessment. A beta of 1.0 means the stock moves in line with the broader market, so it offers no defensive cushion and no special leverage to a market move in either direction.
- Forensic Balance Sheet: 10 / 20. The rating cites Altman Z of 2.5, Piotroski F of 3/9, and Debt/Equity of 0.5. These figures sit in a middle-to-weak zone, which signals balance-sheet fragility rather than robust financial health.
Investor implications: The upside case depends on a turnaround in operating economics, since current cash-based metrics are at zero. The strongest near-term drivers of volatility are the pillars with the lowest scores (institutional flow and insider conviction), which suggest limited support during drawdowns. This is an educational reading of the rating, not personalized financial advice.
2. Business Model, Unit Margins & SEC Financial Trajectory
Haoxi Health Technology Limited (Class A) is a NASDAQ-listed issuer classified under the Communication Services sector and the Advertising industry,. Operating margin is reported at -60% and gross margin at 96% per the market data section.
Revenue declined from $28.2M (FY 2023) to $1.2M (FY 2024) to $0.5M (FY 2025), while free cash flow was negative in each reported year. Net income for FY 2025 ($3.9M) is well above operating income (-$2. Per the market data, ROIC is 0%, FCF yield is 0%, and net margin is 68%. The Altman Z-Score (2.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case: Positive reported FY 2025 net income of $3.9M shows the income statement can diverge favorably from operating results. With Fundamental Cash Engine at 8/20 (ROIC —, FCF yield —) and Institutional Whale Flow at 3/20, sustained execution supports upside toward the top of the $1.60 – $4,352.00 52-week range.
- 🐻 Primary Bear Case: Revenue fell from $28.2M in FY 2023 to $0.5M in FY 2025 while free cash flow stayed negative every year, and the RQD rating is 36 with a D- grade. Investors must weigh current valuation against -60.0% operating margins and a 1.00 macro beta if sector demand softens.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
No upstream or downstream links are recorded, and no proprietary signals are provided. The graph classifies the sector as Communication Services and the industry as Advertising, but records no dependency relationships. A prospective investor should therefore treat second-order ripple effects as unmapped in the source data. Any sector-level sensitivity would have to be inferred from the RQD macro regime pillar (Beta of 1.0), which does not identify specific supplier or customer exposures.
- Key Question #1: Why is FY 2025 net income ($3.9M) positive while operating income (-$2.0M) and free cash flow (-$3.4M) are negative, and what drives the gap?
- Key Question #2: Do the reverse stock split references in the news feed apply to HAO's share structure, and if so, what is the effective ratio and date?
- Key Question #3: What are the company's cash and total debt balances, since the financials report both as N/A?
HAO Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Haoxi Health Technology Limited (Class A) (HAO) • Click "Debate This Headline" to argue it in the Roar Pit below
TradingView report covering Haoxi Health Technology Limited (Class A) (HAO) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Haoxi Health Technology Limited (Class A) (HAO) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Haoxi Health Technology Limited (Class A) (HAO) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Haoxi Health Technology Limited (Class A) (HAO) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Haoxi Health Technology Limited (Class A) (HAO) market action, institutional positioning, and fundamental catalysts.
RTTNews report covering Haoxi Health Technology Limited (Class A) (HAO) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Haoxi Health Technology Limited (Class A) (HAO) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Haoxi Health Technology Limited (Class A) (HAO) market action, institutional positioning, and fundamental catalysts.
HAO Bull vs. Bear Conversation Board — What's Your Call at $1.96?
Positive reported FY 2025 net income of $3.9M shows the income statement can diverge favorably from operating results.
Picked up a starter position in HAO in my $100K Virtual Cash book at $1.92. Positive reported FY 2025 net income of $3.9M shows the income statement can diverge favorably from operating results.. Trading inside a $1.60–$4352.00 52-week range with 0.0% FCF yield gives solid downside support if Advertising multiples expand this quarter.
Both sides have a point here — HAO's 10/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.
Revenue fell from $28.2M in FY 2023 to $0.5M in FY 2025 while free cash flow stayed negative every year, and the RQD rating is 36 with
Revenue fell from $28.2M in FY 2023 to $0.5M in FY 2025 while free cash flow stayed negative every year, and the RQD rating is 36 with a D- grade.. Look at the math on HAO: paying current EV/EBITDA multiples for 0.0% ROIC and -60.0% operating margins leaves zero margin of safety if Advertising demand softens. I'd wait for a retest of $1.69 before getting long.